A CD4-derived peptide carrier blocks acute HIV-1 infection in vitro and binds to gp120 in the presence of Walter-Reed stage 1-6 HIV+ sera. NLM AIDSLINE Important note: Information in this article was accurate in 1993. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


A CD4-derived peptide carrier blocks acute HIV-1 infection in vitro and binds to gp120 in the presence of Walter-Reed stage 1-6 HIV+ sera.

AIDS Res Hum Retroviruses. 1992 Nov;8(11):1945-8. Unique Identifier : AIDSLINE MED/93144004
Ghetie V; Wheeler T; Scott D; Uhr JW; Vitetta ES; Department of Microbiology, University of Texas Southwestern; Medical Center, Dallas 75235-9048.

Abstract: A peptide containing amino acid residues 41-84 of the CD4 molecule was synthesized and coupled through a thioether bond to human serum albumin. This conjugate bound to gp120 with an affinity that was half that of CD4 and blocked the HIV infection in vitro with an efficacy tenfold lower than that of CD4. More importantly, the CD4 peptide-human serum albumin conjugate could bind to gp120 in the presence of HIV+ sera from 18 Walter Reed stage 1-6 patients.
Keywords: Acquired Immunodeficiency Syndrome/*IMMUNOLOGY Antigen-Antibody Reactions Antigens, CD4/*IMMUNOLOGY/METABOLISM Binding, Competitive Dose-Response Relationship, Drug Human HIV Antibodies/*IMMUNOLOGY HIV Envelope Protein gp120/*METABOLISM HIV-1/DRUG EFFECTS/GROWTH & DEVELOPMENT/*IMMUNOLOGY Peptide Fragments/*IMMUNOLOGY/PHARMACOLOGY Serum Albumin/IMMUNOLOGY Support, U.S. Gov't, P.H.S. JOURNAL ARTICLEKWDacquiredimmunodeficiencysyndrome/KWDimmunologyantigen-antibodyreactionsantigens,cd4/KWDimmunology/metabolismbinding,competitivedose-responserelationship,drughumanhivantibodies/KWDimmunologyhivenvelopeproteingp120/KWDmetabolismhiv-1/drugeffects/growth&development/KWDimmunologypeptidefragments/KWDimmunology/pharmacologyserumalbumin/immunologysupport,uKWDsKWDgov't,pKWDhKWDsKWDjournalarticle
930530
M9350967

Copyright © 1993 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1993. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1993. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .